LAUSR

In a recent multicenter, random-order, home-use trial (NCT03565666), we examined automated glycemic control with the insulin-only configuration of the bionic pancreas (BP) using subjects’ typical insulin analogue, BP-T (aspart, n=7 or lispro, n=27), versus using the ultra-rapid faster aspart, BP-F. The dosing algorithm was identical in both arms and used the same setting for insulin absorption speed (tmax=65 minutes). The mean CGM glucose (CGMG) was similar between the BP-F and BP-T arms (154±11 vs. 155±13 mg/dl), as was the median percent time Disclosure J. Sherwood: None. H. Zheng: None. C.A. Balliro: None. L. Ekhlaspour: None. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. F. El-Khatib: Other Relationship; Self; Beta Bionics, Inc. E. Damiano: Board Member; Self; Beta Bionics, Inc. Employee; Self; Beta Bionics, Inc. Stock/Shareholder; Self; Beta Bionics, Inc. Stock/Shareholder; Spouse/Partner; Beta Bionics, Inc. S.J. Russell: Consultant; Self; Beta Bionics, Inc., ConvaTec Inc., Novo Nordisk A/S, Senseonics. Research Support; Self; Beta Bionics, Inc., Novo Nordisk A/S, Zealand Pharma A/S. Stock/Shareholder; Self; Companion Medical. Other Relationship; Self; Ascensia Diabetes Care, Roche Diabetes Care. Funding National Institutes of Health